[Innovations in the treatment of medulloblastoma].
Prognosis of medulloblastoma remains serious with a disease-free survival rate of 70% at 5 years and severe sequelae in the majority of children. In order to improve this survival rate without unacceptable toxicity, various ways are currently under investigation. Among them, hyperfractionation and conformal therapy seem to be promising. Quality control of radiotherapy treatment could surely also play a major role on outcome.
Carrie
C
C
Service de radiothérapie, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France.
Martel-Lafay
I
I
D002528:Cerebellar Neoplasms / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D006801:Humans; D008527:Medulloblastoma / Q000532:radiotherapy*; D011786:Quality Control; D020266:Radiotherapy, Conformal
Innovation dans le traitement du médulloblastome.